Benzinga

Benzinga

Benzinga

mercoledì, settembre 09

Clover Health Investments Corp

CLOVNASDAQ
Trade with Public
Trade with Public
$4.29
0.0350.82%
In chiusura: Sep 8, 5:00 PM EST
$4.29
N/A
Post-mercato: 6:40 PM EST
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoConfrontaOpzioniRapporto azionario

Clover Health Investments Analyst Price Targets

Wall Street analyst price targets and consensus rating for Clover Health Investments (CLOV).

Price Target Range — 7 Quarters

Analyst Consensus — 4 Analysts

2Buy
2Hold
Consensus RatingBuy# Analysts4Avg. Consensus PT$5Upside to Avg. PT+10.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 6, 2026UBSJonathan YongPT RaiseNeutral$5→$5
Jul 21, 2026Canaccord GenuityRichard ClosePT RaiseBuy$4→$6
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
UBS Maintains Neutral on Clover Health Investments, Raises Price Target to $5

UBS analyst Jonathan Yong maintains Clover Health Investments (NASDAQ:CLOV) with a Neutral and raises the price target from $4.75 to $5.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Clover Health Investments, Raises Price Target to $5.5

Canaccord Genuity analyst Richard Close maintains Clover Health Investments (NASDAQ:CLOV) with a Buy and raises the price target from $4.2 to $5.5.
Benzinga Newsdesk

PRO
UBS Maintains Neutral on Clover Health Investments, Raises Price Target to $4.75

UBS analyst Jonathan Yong maintains Clover Health Investments (NASDAQ:CLOV) with a Neutral and raises the price target from $2.75 to $4.75.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Clover Health Investments, Raises Price Target to $4.2

Canaccord Genuity analyst Richard Close maintains Clover Health Investments (NASDAQ:CLOV) with a Buy and raises the price target from $3.2 to $4.2.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Clover Health Investments, Lowers Price Target to $3.2

Canaccord Genuity analyst Richard Close maintains Clover Health Investments (NASDAQ:CLOV) with a Buy and lowers the price target from $3.7 to $3.2.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Clover Health Investments, Maintains $3.7 Price Target

Canaccord Genuity analyst Richard Close maintains Clover Health Investments (NASDAQ:CLOV) with a Buy and maintains $3.7 price target.
Benzinga Newsdesk

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Dati di mercato forniti da API Benzinga

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved